A B S T R A C T Elastase is released from human neutrophils during the early events of blood coagulation. Human plasma kallikrein has been shown to stimulate neutrophil chemotaxis, aggregation, and oxygen consumption. Therefore, the ability of kallikrein to release neutrophil elastase was investigated. Neutrophils were isolated by dextran sedimentation, and elastase release was measured by both an enzyme-linked immunosorbent assay, and an enzymatic assay using t-butoxycarbonyl-Ala-Ala-Pro-Val-amino methyl coumarin as the substrate. Kallikrein, 0.1-1.0 U/ml, (0.045-0.45 ,M), was incubated with neutrophils that were preincubated with cytochalasin B (5 Mg/ml). The release of elastase was found to be proportional to the kallikrein concentration. Kallikrein released a maximum of 34% of the total elastase content, as measured by solubilizing the neutrophils in the nonionic detergent Triton X-100. A series of experiments was carried out to determine if kallikrein was a major enzyme involved in neutrophil elastase release during blood coagulation. When 10 million neutrophils were incubated in 1 ml of normal plasma in the presence of 30 
INTRODUCTION
Granules from viable human neutrophils contain a variety of enzymes known to be released into the extracellular milieu. Enzyme release results from phagocytosis, as well as stimulation by a variety of soluble agents, such as N-formyl-methionyl-leucyl-phenylalanine (FLMP),' or the plasma chemotaxin, C5a (1) . One of the more important neutrophil enzymes found in the azurophilic granules is elastase (EC 3.4.21.37), which may be responsible for proteolysis of vital structures in the lung (2) . Plow (3) has shown that, in vitro, human neutrophils release elastase during blood coagulation, independently of thrombin. Purified human plasma kallikrein, which is a chemotoxin for neutrophils (4) as well as a stimulator of aerobic glycolysis in neutrophils (5) , also aggregates human neutrophils, and stimulates oxygen consumption (6) . This effect, which requires the active enzyme, occurs at kallikrein concentrations that may occur during blood coagula-I Abbreviations used in this paper: DFP-HNE, diisopropylfluorophosphate-inactivated HNE; ELISA, enzyme-linked immunosorbent assay; FMLP, N-formyl-methionyl-leucylphenylalanine; HNE, human neutrophil elastase; SBTI Neutrophil isolation. Human neutrophils were isolated from blood and anticoagulated with acid-citrate-dextrose by sedimentation in 1% dextran (Mr = 100,000-200,000), followed by a brief hypotonic or NH4Cl lysis of residual erythrocytes (11, 12) . From one unit of whole blood, we isolated -=8 X 108 neutrophils to --80% purity.
Neutrophil release in a purified system. 10 million isolated neutrophils were incubated in 1 ml of Hanks' balanced salt solution containing 2 mM CaC12, at 37°C, while stirring at 1,200 rpm in the presence of 5 jAg/ml cytochalasin B (13).
After 20 min, various agonists were added to this incubation mixture. Upon centrifugation at 13,000 g for 5 min at 23°C in a Micro-Centrifuge (model 235A Fisher Scientific Co., Pittsburgh, PA), the supernatants were recovered and frozen at -20°C until enzymes were measured.
Neutrophil release in a plasma system. Neutrophils (1 X 107/ml) not primed with cytochalasin B were resuspended in normal or factor-deficient plasma, without stirring, at 23°C, in polypropylene tubes. Then CaC12 (final concentration 30 mM) was added, and 1-ml samples were aliquoted. At various times, SBTI (250 ,M final concentration) was added, and each sample was centrifuged at 13,000 g for 5 min at 23°C.
Fluorimetric measurement of neutrophil elastase. Neutrophil elastase activity, released in a purified system as described above, was measured, using the fluorescent substrate, t-butoxycarbonyl-Ala-Ala-Pro-Val-amino methyl coumarin (7) . The percent of elastase activity released was calculated, relative to the total elastase activity, as determined by solubilizing intact neutrophils in 0.5% Triton X-100 (14) .
Enzyme 
RESULTS
Release of elastase from washed human neutrophils by plasma kallikrein. Purified human plasma kallikrein, 0.1-1.0 U/ml (0.045-0.45,M), induced neutrophils primed with cytochalasin B to release 12-34% of their total elastase content. Kallikrein, (0.05 U/ml, 0.023 AM) released only 2% elastase, which did not differ significantly from the buffer control. In the absence of cytochalasin B, only 1-3% release was found. The release of the enzyme was determined by a functional assay for elastase, using the fluorescent substrate (Fig. 2) . This release was not due to cell lysis, since <2% of the lactate dehydrogenase that can be solubilized by 0.5% Triton X-100 appeared in the supernatant. Neutrophils incubated with human plasma prekallikrein (0.45 MM, 1 U/ml), human plasma Factor XII fragments (1.0 Mg/ml), human urinary kallikrein (0.45 MM), SBTI-inactivated kallikrein (0.45 MM), or calcium alone, failed to release significant levels of HNE and showed an absolute requirement for calcium (Table I) . To assess the kinetics of the elastase released, purified human plasma kallikrein, 1.0 U/ml (0.45 MM), was incubated with neutrophils that were primed with cytochalasin B in Hanks' balanced salt solution, which contained no plasma. Aliquots were removed at various times, and the kallikrein was inactivated with SBTI (250 MM). At this concentration, 550-fold excess of inhibitor over enzyme, complete inactivation of kallikrein by SBTI was achieved in 5 s. Within 15 s. of addition of kallikrein to neutrophils, 1.31±0.06 Mg (Fig. 4) . Since kallikrein formation in plasma is influenced by the surface composition of the tube used, we measured elastase release in polystyrene and glass tubes under similar conditions. At 2 min, the percentage maximum release of elastase in polypropylene, polystyrene, and glass tubes, was 28, 28, and 100%, respectively. At 5 min, the corresponding values were 31, 92, and 100%, respectively. Thus, the release of elastase appeared to be very sensitive to the nature of the vessel surface, with release most rapid in glass, followed by polystyrene, and polypropylene.
Release of elastase in human deficient plasma. Since kallikrein could release elastase in a purified system, and since the nature of the surface profoundly influenced the role of elastase release, we studied neutrophil activation in plasma from individuals deficient in the contact system enyzmes. When Factor XI-deficient plasma was used (Fig. 4) , the level of elastase released was similar to that in normal plasma. To assess the contribution of kallikrein during this process, 107 neutrophils were resuspended in 1 ml of either prekallikrein-deficient or Factor XII-deficient plasma. When CaCl2 was added (30 mM) to the cells resuspended in either prekallikrein-deficient or Factor XII-deficient plasma, less than half of the concentration of elastase was released, as compared with normal plasma (Fig. 4) . were resuspended in 1 ml of (0) Upon reconstitution of the prekallikrein-deficient plasma with purified prekallikrein, 1.0 U/ml (0.45 ,uM), the level of neutrophil elastase released approached the level that was observed in normal plasma (Fig. 5) . The measureable formation of plasma kallikrein exposed to a surface is twice as great in plasma depleted of Cl-inhibitor, the major inhibitor of kallikrein (9) . Therefore, we compared the maximum extent of elastase release from the same neutrophils resuspended in normal and Cl-inhibitor deficient plasma. The release was 2.3-fold higher in the plasma from the patient with hereditary angioedema.
To assess the role of C5a in the release of elastase during coagulation, neutrophils were resuspended in C5-deficient plasma. After incubation in the presence of calcium, no difference in elastase release was noted, as compared with that of neutrophils resuspended in normal plasma (Fig. 6) . Finally, 100 Ml of anti-C5 IgG (17.7 mg/ml) was preincubated with 1 ml of normal plasma for 20 min, at 37°C. When neutrophils (107/ ml) were resuspended in normal plasma, or normal plasma preincubated with antibody, 3.5,ug/ml elastase released was observed in both mixtures.
DISCUSSION
The data presented here support the conclusions that purified plasma kallikrein not only serves as a chemotaxin (4), aggregating agent (6) , and stimulator of oxidative metabolism for human neutrophils (5, 6), but also induces the cells to release elastase in a purified (0) (20, 21) , it is possible that C5a could be responsible for at gulation, the for-least part of the elastase release during coagulation.
major stimulator Furthermore, rabbit plasma kallikrein is known to produce chemotactic activity of rabbit C5 (22) . To further rein released elas-probe these relationships, we resuspended human neuoreincubated with trophils in human C5-deficient plasma. The similarity filament function. of elastase release in C5-deficient and normal plasma iS detected in the argues against a significant role for C5a in elastase ical and electron release during coagulation. Furthermore, preincubation hils, primed with of normal plasma with anti-C5 did not inhibit elastase Af lysosomal gran-release. However, this finding does not detract from lasma membrane the importance of C5a under other conditions. nzymes normally Plow (3) reported that neutrophils were the only vithin phagocytic significant source of immunoreactive HNE in blood. material may be Furthermore, he demonstrated that elastase was resin B when neu-leased from neutrophils during coagulation. However, ible surface, such he reported a markedly lower level of elastase release known what com-at 37°C, than we did at 230C. This discrepancy can ts this release of be explained by the fact that kallikrein, the enzyme responsible for this release, is inactivated by plasma trophils by kalli-protease inhibitors more rapidly at 37 than at 23°C. on period. How-In addition, the major plasma protease inhibitor of was extruded ex-kallikrein, CI-inhibitor, is less active at 23 than at reaction. This be-370C, thereby allowing us to observe a greater effect of Sklar et al. (19) of kallikrein on the neutrophils. We also observed xposure to zymo-greater release of neutrophil elastase in plasma defiPhis rapid release cient in CI-inhibitor. eakage of lactate
The participation of kallikrein in neutrophil actis, indicating that vation and elastase release expands our appreciation inducing granule of the role of this enzyme in human disease. A number 'ct on the neutro-of diseases in which prekallikrein activation has been established, such as hypotensive endotoxemia (23) , are known to be associated with neutrophil activation. Although complement activation has been implicated, kallikrein should be considered as an additional agonist. Furthermore, since neutrophil aggregation has been demonstrated in the lungs of patients with adult respiratory distress syndrome, elastase may be released in that disorder, via the mediation of plasma kallikrein.
